Some new biopharma companies move remarkably fast in bringing drug candidates into the clinic and even to market. This is not such a case, however. After more than five years and a venture capital top-up to a total of $75 million last year, Kolltan Pharmaceuticals Inc. hopes to bring a lead monoclonal antibody for cancer to the IND-submission stage before the end of 2013.
The biotech works in areas similar to Pfizer Inc.’s renal cell carcinoma and gastrointestinal cancer drug Sutent (sunitinib), which...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?